Skip to main content

Organon & Co.(OGN-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA* - Thu Oct 26, 2023

KIRKLAND, QC, Oct. 26, 2023 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced the availability of HADLIMA® (adalimumab), a biosimilar for Humira* (adalimumab), in a high-concentration, citrate free (40 mg/0.4 mL) version. The launch of the new higher concentration formulation (40 mg/0.4 mL) (compared to HADLIMA® 40 mg/0.8 mL) offers physicians and patients with more options for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, ankylosing spondylitis (AS), psoriatic arthritis, adult Crohn's disease, ulcerative colitis, adult and adolescent hidradenitis suppurativa, plaque psoriasis, adult and pediatric uveitis.1 


Provided Content: Content provided by The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe